Potential Impact of Optimal Implementation of Evidence-Based Heart Failure Therapies on Mortality

Study Questions:

Does utilization of six therapies including angiotensin-converting enzyme inhibitor/angiotensin-receptor antagonist, beta-blockers, aldosterone receptor blockers, hydralazine/nitrate combinations, cardiac resynchronization therapy, and implantable cardioverter-defibrillators impact mortality of patients with systolic heart failure (HF) in a “real-world setting”?